Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer

Launched by RABIN MEDICAL CENTER · Feb 22, 2010

Keywords

ClinConnect Summary

The optimal treatment of patients with laryngeal cancer remains controversial. Standard treatment options have included laryngectomy with or without radiation (RT) and radiation alone with surgical salvage (RTSS).

Because of the significant functional morbidity associated with laryngectomy, the Department of Veterans Affair Cooperative Studies Program completed a randomized, prospective study of 332 patients that compared a new organ preservation treatment strategy to conventional laryngectomy and radiation. The experimental treatment arm involved three cycles of neoadjuvant chemotherapy f...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must have pathologically confirmed previously untreated, resectable, squamous cell carcinoma of the larynx.
• • Disease must be Stage III or IV.
• • Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy.
• • Patients must undergo pre-treatment endoscopic tumor staging and CT scanning of chest and neck.(pet scan optional)
• • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
• * Pre-treatment laboratory criteria:
• • WBC \> 3500/ul, granulocyte \> 1500/ul.
• • Platelet count \> 100,000/ul.
• • Calculated or measured creatinine clearance \> 60 cc/min.
• • AST and ALT \< 2.5 X ULN
• • Patients must give documented informed consent to participate in this study.
• Exclusion Criteria:
• • Prior head and neck malignancy or active non-head and neck malignancy. Except for cured non-melanoma skin cancer,
• • Prior head and neck radiation.
• • Documented evidence of distant metastases.
• • Active infection.
• • Pregnancy or lactation. Patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
• • Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment.
• • Age \< 18 years.
• • Patients with psychiatric/social situations that would limit compliance with study requirements are not eligible.
• • Patients with Grade \> 2 peripheral neuropathy.
• • Any history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
• • Criteria for supracricoid resection for chemo selection non responders
• Inclusion Criteria :
• • At least one functional arytenoids (physical and radiological examinations)
• • Involvement of thyroid cartilage including extrathyroid cartilage extension.
• Exclusion criteria:
• • Subglottic extension anteriorly.
• • Pre epiglottic extension.
• • Subglottic extension laterally.
• • Interarytenoid involvement.
• • Two Arytenoids involved.
• Criteria for supracricoid resection for Chemoradiation failure:
• Inclusion Criteria:
• • At least one functional arytenoid (physical and radiological examinations)
• • Involvement of thyroid cartilage (with no radiological evidence for extra thyroid Extension).
• Exclusion Criteria:
• • Extrathyroid cartilage extension.
• • Involvement preepiglottic space.
• • Subglottic extension.
• • Interarytenoid involvement.